Investor Presentation

31st October 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd. BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Pheroze Jeejeebhoy Tower, Bandra-Kurla Complex, Bandra (E), Dalal Street, Mumbai- 400 001 Mumbai - 400 051 Security Code: 524164 Security Symbol: IOLCP Subject: Investor Presentation-Q2 & H1 FY27. Dear Sir, Please find enclosed herewith the Investor Presentation on the Financial Results of the Company for the quarter and half year ended 30th September 2026. This presentation is being submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This presentation is also made available on the Company’s website www.iolcp.com Hope you will find the same in order. Thanking You, Yours faithfully, for IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr. Vice President & Company Secretary IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q2 & H1 FY27 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by IOL Chemicals and Pharmaceuticals Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Q2 & H1 FY27 Performance Q2 & H1 FY27 Standalone Performance Highlights ₹ 795.0 Cr Q2 FY27 ₹ 65.0 Cr ₹ 114.9 Cr Revenue from Operations EBITDA 40.1% YoY 79.6% YoY 116.8% YoY EBITDA Margin 14.4% PAT Margin 8.1% H1 FY27 ₹ 1551.3 Cr ₹ 226.6 Cr ₹ 129.5 Cr Revenue from Operations EBITDA PAT 38.6% YoY 69.7% YoY 102.5% YoY EBITDA Margin 14.5% PAT Margin 8.3% Q2 & H1 FY27 Standalone Performance Highlights Pharmaceuticals Chemicals (Net of intersegment) Geographical Break-up (In ₹ Cr) (In ₹ Cr) 942.2 469.5 472.8 609.1 322.3 28% 286.8 665.7 336.4 453.5 231.2 136.9 68.8 68.1 75.5 35.5 40.5 17.3 23.2 11.0 5.1 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY27 EBIT Revenue EBIT Revenue Exports Domestic Standalone Profit & Loss Statement – Q2 & H1 FY27 Particulars (in INR Cr.) Q2 FY27 Q2 FY26 Y-o-Y Q1 FY27 Q-o-Q H1 FY27 H1 FY26 Y-o-Y Revenue from Operations 795.0 567.5 40.1% 756.3 5.1% 1551.3 1119.2 38.6% Other Income 5.5 6.9 8.2 13.7 14.3 Total Revenue 800.5 574.4 39.4% 764.4 4.7% 1565.0 1133.5 38.1% Cost of Materials Consumed 505.3 366.7 506.8 1012.1 743.3 Purchase of Traded Goods 0.0 0.0 0.8 0.8 Changes in Inventories of Finished Goods and Work in Progress -4.0 1.5 -29.5 -33.5 -10.9 Employee Benefits Expense 68.7 63.4 71.2 139.9 121.0 Other Expenses 115.6 78.9 103.5 219.2 146.6 EBITDA 114.9 64.0 79.6% 111.7 2.8% 226.6 133.5 69.7% EBITDA % 14.4% 11.1% 14.6% 14.5% 11.8% Depreciation and Amortisation Expense 22.2 20.0 21.3 43.5 39.7 EBIT 92.7 44.0 110.7% 90.4 2.5% 183.1 93.8 95.3% Finance Costs 5.4 3.5 3.6 9.1 7.7 Profit before exceptional items and tax 87.2 40.5 115.3% 86.8 0.6% 174.0 86.1 102.2% Exceptional items* 0.0 0.0 0.0 0.0 0.0 PBT 87.2 40.5 115.3% 86.8 0.6% 174.0 86.1 102.2% Total Tax Expense 22.2 10.5 22.3 44.5 22.1 Profit after tax 65.0 30.0 116.8% 64.5 0.9% 129.5 64.0 102.5% PAT % 8.1% 5.2% 8.4% 8.3% 5.6% EPS 2.21 1.02 2.20 4.41 2.18 Standalone Balance Sheet Particulars (in INR Cr.) Sep 26 Mar 26 Particulars (in INR Cr.) Sep 26 Mar 26 ASSETS EQUITY ANDLIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1,170.5 1165.1 (i) Equity share capital 58.7 58.7 (ii) Right to Use Asset 6.9 3.4 (ii) Other equity 1,866.8 1,739.7 (iii) Capital Work in progress 189.4 93.6 Total Equity 1,925.5 1798.4 (iv) Other Intangible Assets 13.2 12.8 LIABILITIES (v) Intangible Assets under development 0.0 1.9 Non-current liabilities (vi) Financial Assets (i) Financial Liabilities - Investments 17.7 17.6 -Borrowings - Other Financial Assets 43.0 45.1 -Lease Liabilities 5.4 2.4 (vii) Other Non-CurrentAssets 23.8 19.7 (ii) Provisions 12.3 11.0 Total Non-current assets 1464.5 1359.2 (iii) Deferred tax Liabilities (net) 86.0 84.9 (iv) Other Non-Current Liabilities Current assets Total Non-Current Liabilities 103.6 98.2 (i) Inventories 464.4 371.1 Current liabilities (ii) Financial Assets (i) Financial liabilities - Investments 3.7 3.5 -Borrowings 194.2 132.0 - Trade receivables 689.2 603.1 -Lease Liabilities 1.7 1.0 - Cash and cash equivalents 9.2 65.3 -Trade payables 487.8 482.6 - Bank balances other than above 117.1 133.0 -Other financial liabilities 70.4 50.7 - Other financial Assets 6.1 7.5 (ii) Other Current Liabilities 29.8 18.1 (iii) Current Assets (net) (iii) Provisions 5.0 3.4 (iv) Other Current Assets 76.5 44.1 (iv) Current Tax Liabilities 12.5 2.4 Total Current Assets 1,366.0 1227.5 Total Current Liabilities 801.3 690.1 TOTALASSETS 2,830.4 2586.7 TOTAL EQUITY AND LIABILITIES 2,830.4 2586.7 Standalone Cash Flow Statement Particulars (in INR Cr.) Sep 26 Sep 25 Cash Flow from Operating Activities Profit before Tax 174.0 86.1 Adjustment for Non-Operating Items 41.8 41.1 Operating Profit before Working Capital Changes 215.8 127.1 Changes in Working Capital 175.0 100.1 Cash Generated from Operations 40.8 27.0 Less: Direct Taxes paid -32.5 -15.9 Net Cash from Operating Activities 8.3 11.1 Cash Flow from Investing Activities -116.8 -96.2 Cash Flow from Financing Activities 52.4 34.2 Net increase/ (decrease) in Cash & Cash equivalent -56.1 -50.9 Cash and cash equivalents at the beginning of the year 65.3 78.0 Cash and cash equivalents at the end of the year 9.2 27.2 Strategic Initiatives ₹495 Cr 3 Total Planned Investment Strategic Projects Ibuprofen Capacity Expans [Showing first 8,000 characters — download PDF for full document]